Repare Rx - RPTX Quarterly EPS earnings growth

Corporate company logo of Repare Therapeutics Inc. (RPTX)

The quarterly EPS change demonstrates volatility, with 109.90 characterizing this valuation parameter for Repare Therapeutics (RPTX). Growth is supported by unique patents in synthetic lethality and pricing power. However, price action is pressured by geopolitical complexities regarding drug registration, as well as a heavy reliance on external research organizations for the development of targeted therapies.

reparerx.com (RPTX) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 02/07/2026

Analytical breakdowns for Repare Therapeutics

- share price and consensus valuation forecast:
Stock Quotes Repare Therapeutics Inc.|RPTX - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Repare Therapeutics Inc|RPTX - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Repare Therapeutics|RPTX - Accounting Value of Company|Market Capitalization to Book Value Ratio reparerx.com|RPTX - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Repare Therapeutics|RPTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Repare Therapeutics|RPTX - Company Cumulative Indebtedness|Debts to Book Capitalization Repare Rx|RPTX - Long-Term Debt|Company Short-Term Debts Repare Therapeutics|Quick Liquidity Indicator reparerx.com
- earnings and market multiples details:
RPTX - Final Profit|Future Profit Repare Therapeutics|RPTX - Market Price to Net Income Ratio|Forward P/E Multiple Repare Therapeutics|RPTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Repare Rx|RPTX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Repare Therapeutics|RPTX - Earnings per share for the trailing year|Quarterly EPS earnings growth reparerx.com|RPTX - Earnings growth in current year|Net earnings per share growth forecast for next year Repare Therapeutics
- sales revenue and business income indicators:
RPTX - Company Annual Revenue|Company Future Sales Volume reparerx.com|RPTX - Price to Sales|Price-to-Projected Revenue Ratio Repare Therapeutics Inc.
Fundamental company valuation:reparerx.com - RPTX
Flagship merchandise of reparerx.com

Repare Therapeutics (RPTX) lacks its own production facilities, shifting the analytical focus to the quarterly EPS growth rate, which provides an immediate market reaction to financial results. This metric measures the dynamics of net income per share, allowing investors to assess the sustainability of the business model and timely identify the risk of purchasing the asset at a price peak.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Inc. IMRX|Quarterly EPS earnings growth CCCC|Black Diamond Therapeutics - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)